Add Yahoo as a preferred source to see more of our stories on Google. Jul. 16—Local students put their skills and knowledge to the test during a chess camp held at Northeastern State University. The ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial. m, median; NE, not ...

NE, not estimable; NR, not reached. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.